Oral Cancer News

It’s True. You Can Get Throat Cancer From Oral Sex

By: Alexandra SifferlinJune 03, 2013 Source: TIME On Sunday, in an interview with the Guardian, actor Michael Douglas revealed that his throat cancer was not caused by tobacco and alcohol, but by HPV, which was transmitted through oral sex. He has since called the statement a misunderstanding, but it’s still true: you can get throat cancer from HPV. In an eye-poppingly candid interview with the Guardian’s Xan Brooks, Douglas, who is married to actress Catherine Zeta-Jones, allegedly told the reporter his cancer was caused by the STD: The throat cancer, I assume, was first seeded during those wild middle years, when he drank like a fish and smoked like the devil. Looking back, knowing what he knows now, does he feel he overloaded his system? “No,” he says. “No. Because, without wanting to get too specific, this particular cancer is caused by HPV [human papillomavirus], which actually comes about from cunnilingus.” From what? For a moment I think that I may have misheard. “From cunnilingus. I mean, I did worry if the stress caused by my son’s incarceration didn’t help trigger it. But yeah, it’s a sexually transmitted disease that causes cancer.” He shrugs. “And if you have it, cunnilingus is also the best cure for it.” Right, I say. OK. So what he is suggesting is that it all evens out? “That’s right,” says Douglas. “It giveth and it taketh.” Human papillomavirus (HPV) is a sexually transmitted disease that can cause genital warts or present itself without symptoms. If left untreated, it can also [...]

Charlotte Parker2013-06-04T11:13:31-07:00June, 2013|Oral Cancer News|

Fact check: Michael Douglas on HPV and throat cancer

Source: www.huffingtonpost.com Author: Meredith Melnick A Michael Douglas interview in The Guardian caused waves when the publication reported that the "Behind the Candelabra" star revealed HPV, the human papilloma virus, to be the cause of his stage-4 throat cancer diagnosis in 2010. "Without wanting to get too specific, this particular cancer is caused by HPV, which actually comes about from cunnilingus," Douglas allegedly told The Guardian. Douglas, through his publicist, has said that the statement was misinterpreted: He wasn't saying that his cancer was caused by the sexually transmitted disease -- merely that many cancers like his are HPV-positive. As The Daily Beast points out, there is scant research evidence to directly link the act of cunnilingus with HPV infection. But regardless of the details of his own cancer, the actor is right about one thing: A growing majority of oral cancer cases are caused by HPV. While most strains of HPV clear up on their own, the sexually transmitted disease is responsible for an array of cancers. As Douglas describes, it's true that oral sex is an avenue through which a person can contract HPV and especially the strains, HPV-18 and HPV-16, the latter of which is responsible for half of oral cancer cases, according to the National Cancer Institute. HPV-16, HPV-18 and some less-common strains can also cause cancers of the cervix, vagina, vulva, anus and penis. Douglas' experience follows trends in cancer diagnosis, according to a January report from the American Cancer Society, which found a rise [...]

Oral Cancer Foundation News Team - A2013-06-04T07:22:57-07:00June, 2013|Oral Cancer News|

Oral cancer prognosis based on clinicopathologic and genomic markers using a hybrid of feature selection and machine learning methods

Source: 7thspace.com Author: staff Machine learning techniques are becoming useful as an alternative approach to conventional medical diagnosis or prognosis as they are good for handling noisy and incomplete data, and significant results can be attained despite a small sample size. Traditionally, clinicians make prognostic decisions based on clinicopathologic markers. However, it is not easy for the most skilful clinician to come out with an accurate prognosis by using these markers alone. Thus, there is a need to use genomic markers to improve the accuracy of prognosis. The main aim of this research is to apply a hybrid of feature selection and machine learning methods in oral cancer prognosis based on the parameters of the correlation of clinicopathologic and genomic markers. Results: In the first stage of this research, five feature selection methods have been proposed and experimented on the oral cancer prognosis dataset. In the second stage, the model with the features selected from each feature selection methods are tested on the proposed classifiers. Four types of classifiers are chosen; these are namely, ANFIS, artificial neural network, support vector machine and logistic regression. A k-fold cross-validation is implemented on all types of classifiers due to the small sample size. The hybrid model of ReliefF-GA-ANFIS with 3-input features of drink, invasion and p63 achieved the best accuracy (accuracy = 93.81%; AUC = 0.90) for the oral cancer prognosis. Conclusions: The results revealed that the prognosis is superior with the presence of both clinicopathologic and genomic markers. The selected features can [...]

Oral Cancer Foundation News Team - A2013-06-03T10:50:00-07:00June, 2013|Oral Cancer News|

Researchers discover potential biomarkers to identify patients with head and neck cancer

Published on June 1, 2013 at 4:16 AMSource: news-medical.net Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody. The FDA approved the drug, in combination with radiation or as a second-line drug after chemotherapy had failed, in 2006. In 2011, the drug was approved as a first-line treatment for metastatic disease, in combination with chemotherapy. "Targeted therapies should optimally be used in patients who are selected for sensitivity or the absence of sensitivity, and we've been handicapped by not knowing the resistance in head and neck cancers," says Barbara Burtness, MD, chief of head and neck medical oncology at Fox Chase and chair of the Eastern Cooperative Oncology Group (ECOG), a National Cancer Institute-funded team of researchers who organize and carry out clinical trials. Before cetuximab, head and neck cancer patients' only options were conventional platinum-based chemotherapy and radiation, says Burtness. But since tumors in different people may have different biologies, not all patients respond to same treatment in the same ways. Those whose tumors do not respond to cetuximab suffer the drug's side effects without gaining benefits. Biomarkers can help providers match appropriate treatments to disease. They may also provide inroads toward re-sensitizing tumors to treatment by [...]

Charlotte Parker2013-06-03T10:31:21-07:00June, 2013|Oral Cancer News|

PTEN loss, PIK3CA mutation predicted resistance to cetuximab in HNSCC

June 2, 2013Source: Helio.com CHICAGO — PTEN loss or PIK3CA mutation predicted resistance to treatment with cisplatin plus cetuximab in a cohort of patients with head and neck squamous cell carcinoma, according to phase 3 study results presented at the ASCO Annual Meeting. “Cetuximab is the only targeted therapy in use in head and neck cancer, and although it prolongs survival, the effects are modest. For patients who receive [cetuximab] in the setting of metastatic or recurrent disease, median survival remains less than 1 year,” Barbara Burtness, MD, a medical oncologist at Fox Chase Cancer Center who specializes in head and neck cancers and a HemOnc Today Editorial Board member, said in an interview. “In colon cancer, patients are tested for KRAS mutations to detect patients with upfront resistance to cetuximab, but KRAS mutation is rare in head and neck cancer, and we haven’t had a biomarker to separate the sensitive from resistant patients.” Burtness and colleagues compared cisplatin plus placebo vs. cisplatin plus cetuximab (Erbitux, Eli Lilly) in 117 patients. The researchers also assessed PIK3CA mutations and loss of PTEN expression in the cohort. Results indicated that 34% of tumors studied had a loss of PTEN expression and 4% had PIK3CA mutations in the three hotspots studied. Researchers did not observe any statistically significant differences in OS, PFS or overall response rates. However, among patients with PIK3CA and PTEN expression, median PFS was 4.2 months for those assigned to cetuximab vs. 2.9 months for those assigned to placebo (adjusted [...]

Charlotte Parker2013-06-03T10:20:56-07:00June, 2013|Oral Cancer News|

No increased risk of infection for long-term sex partners of people with HPV-related oral cancers

June 1, 2013 in Cancer Source: Medical Express Spouses and long-term partners of patients with mouth and throat cancers related to infection with the human papilloma virus (HPV) appear to have no increased prevalence of oral HPV infections, according to results of a multicenter, pilot study led by Johns Hopkins investigators. The study's results suggest that long-term couples need not change their sexual practices, say the scientists. "While we can't guarantee that the partners of patients will not develop oral HPV infections or cancers, we can reassure them that our study found they had no increased prevalence of oral infections, which suggests their risk of HPV-related oral cancer remains low," says Gypsyamber D'Souza, Ph.D., M.P.H., associate professor of epidemiology at the Johns Hopkins University Bloomberg School of Public Health. She is expected to present the results of her study June 1 at the 2013 American Society of Clinical Oncology Annual Meeting. HPV-related oral cancers are rising in prevalence among white men in the United States, and fear of transmitting the virus can lead to anxiety, divorce, and curtailing of sex and intimacy among couples, says D'Souza. Persistent oral HPV infections are a risk for developing oropharyngeal cancers, located at the base of the tongue, tonsils, pharynx and soft palate. At the Johns Hopkins Hospital and three other hospitals, researchers conducted surveys and took oral rinse samples from 166 male and female patients with HPV-related oropharyngeal cancers and 94 spouses and partners. The scientists also studied patients' tumor samples and performed visual [...]

Charlotte Parker2013-06-03T10:07:24-07:00June, 2013|Oral Cancer News|

Michael Douglas: Oral sex gave me cancer

By DAVID K. LISource: NewYork PostLast Updated: 11:31 AM, June 3, 2013Posted: 8:49 PM, June 2, 2013 Michael Douglas has made a jaw-dropping revelation about his throat cancer: He didn’t contract it from smoking or drinking — but from oral sex. The Oscar-winning Hollywood star set tongues wagging after he told The Guardian newspaper that he contracted HPV, or human papillomavirus, through a sex act and it developed into cancer. “Without wanting to get too specific, this particular cancer is caused by HPV, which actually comes about from cunnilingus,” he told the British newspaper in an interview published yesterday. After Douglas was diagnosed with the life-threatening illness in 2010, he said on “Late Show with David Letterman” that the kind of cancer he had was caused by smoking and drinking. Ghetty Images Actor Michael Douglas said a virus from oral sex, not booze and cigarettes, gave him throat cancer. In yesterday’s interview, the 68-year-old actor speculated that his son Cameron’s legal woes may have borne some responsibility, too. “I did worry if the stress caused by my son’s incarceration didn’t help trigger it,” the “Wall Street” actor said of Cameron Douglas, who is serving 10 years in a federal prison for heroin possession and distribution. “But, yeah, it’s a sexually transmitted disease that causes [the] cancer.” A cancer-awareness advocate hailed Douglas for his blunt talk. “I’m really quite proud of Michael saying this,” Brian Hill, executive director of the Oral Cancer Foundation, told The Post yesterday. “This [oral sex] is [...]

Charlotte Parker2013-06-03T09:50:47-07:00June, 2013|OCF In The News, Oral Cancer News|

The Oral Cancer Foundation Honored as 2013 Top-Rated Nonprofit New GreatNonprofits.org Award is Based on Positive Online Reviews

Newport Beach, CA May 28, 2013 - The oral Cancer Foundation announced today that is has been honored with a prestigious 2013 Top-Rated Awarded by GreatNonprofits, the leading provider of user reviews about non-profit organizations. "We are honored to be named a Top-Rated 2013 Nonprofit," says Brian hill, Founder and Executive Director, The Oral Cancer Foundation. "We have found creative means to accomplish our missions; raise awareness, support patients, provide information, and sponsor research to accomplish important goals when our human and financial resources were minimal." The Top-Rated Nonprofit award was based on a large number of positive reviews that OCF received - reviews written by the patient population they serve and donors. Individuals could contribute more than a yes/no answer about questions regarding their personal experiences with the non-profit. For example, one person wrote, "I was 33 years old when I was diagnosed with Stage IV metastatic oral cancer. The treatments and surgeries that saved my life however left me disfigured, disabled and dependent on the opiate pain medication, Fentanyl. I felt lost and alone, without hope. I found the Oral Cancer Foundation website 11 months after diagnosis and it was a ray of light for me. I was able to connect with survivors and other patients who understood my struggle and related to where I was. With their advice and support I've been able to rebuild my body and free myself from the opiates, and begin to live again. I can't express the gratitude in my [...]

Charlotte Parker2013-05-29T16:05:54-07:00May, 2013|OCF In The News, Oral Cancer News|

Noninvasive Detection, Diagnosis of Oral Cancer

Source: Science DailyDate: May 23, 2013 More effective detection and diagnosis of oral cancer could result from an advance in noninvasive imaging of epithelial tissue by a Texas A&M University researcher. The research is thought to have the potential to change the way doctors initially look for precancerous and cancerous areas in a patient's mouth. The imaging technique, which is detailed in the Journal of Biomedical Optics, is being developed by Kristen Maitland, assistant professor in the university's Department of Biomedical Engineering. It combines two separate technologies -- confocal microscopy and fluorescence lifetime imaging -- to noninvasively evaluate both the structural changes of tissue as well as molecular changes that take place on a cellular and tissue level. These morphological and biochemical changes are key factors in determining if tissue is precancerous or cancerous, Maitland says. Fluorescence lifetime imaging with a 16x16 mm2 field of view detects tissue biochemical changes on the macroscopic scale, and (inset) confocal microscopy with a 0.4 mm diameter field of view is used to characterize size, shape, and spacing of cell nuclei to detect oral precancer and cancer (Credit: Texas A&M University) Typically, such evaluations are made from lab analysis of biopsies, small amounts of surgically removed tissue. The challenge for doctors, Maitland says, is determining from what areas to take a biopsy. These determinations, she says, are largely based on visual evidence. In other words, doctors rely on the naked eye to look for problematic areas that warrant a biopsy. For [...]

Charlotte Parker2013-05-28T14:02:44-07:00May, 2013|Oral Cancer News|

U.S. panel finds lack of evidence for oral cancer screening

Source: Dr. BicuspidBy: Dr. Bicuspid StaffApril 9, 2013 A U.S. government-backed task force issued a statement this week saying that there is not enough published evidence to recommend for or against screening for oral cancer by primary care professionals. Evidence is lacking on whether screening can accurately detect oral cancer and if earlier treatment of cancers found during those tests improves long-term health, according to the U.S. Preventive Services Task Force (USPSTF). Their draft recommendation statement applies to people who do not have any signs or symptoms of oral cancer and is meant for primary care professionals screening for oral cancer. It is not a recommendation about the practices of dentists and oral health professionals, the panel noted. The task force -- an independent volunteer panel of national experts in prevention and evidence-based medicine -- reviewed the current literature and found: Inadequate evidence that the oral screening examination accurately detects oral cancer Inadequate evidence that screening for oral cancer and treatment of screen-detected oral cancer improves morbidity or mortality Inadequate evidence on the harms of screening; no study reported on harms from the screening test or from false-positive or false-negative test results Seven studies (n = 49,120) examined the performance characteristics of the oral screening examination. These studies were generally conducted in settings with an increased incidence of and mortality from oral cancer (India, Taiwan) compared with U.S. rates, the panel reported. The studies also had considerable heterogeneity and demonstrated great variation in test performance characteristics. Across the seven studies, sensitivity [...]

Charlotte Parker2013-05-26T07:36:08-07:00May, 2013|OCF In The News, Oral Cancer News|